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California San Diego, CA, USAAbstractWe detected hepatitis B virus (HBV) DNA in the cerebrospinal
ﬂuid (CSF) of 26 adolescents co-infected with human
immunodeﬁciency virus (HIV) and hepatitis B virus (HBV) with
neurological disease and studied compartmentalization of HBV in
the CSF. More than half of the subjects with positive HBV DNA
plasma also had CSF positive for HBV. CSF HBV DNA was found
in subjects with preserved blood–brain barrier integrity. In a
subgroup of these subjects, compartmentalized evolution of HBV
was demonstrated by distinct proﬁles of resistance mutations.
Future studies are warranted to determine the clinical
signiﬁcance of HBV presence in the CSF and its contribution to
HIV-associated neurological disease.
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D. Duiculescu, deceased, 14 March 2014IntroductionNon-hepatic reservoirs of hepatitis B virus (HBV) have been
demonstrated in neuronal cells [1]. Unique nucleotide sub-
stitutions were found in the HBV sequences from the cere-
brospinal ﬂuid of a patient with transverse myelitis [2]. Few data
exist on the impact of HBV in the central nervous system
(CNS) of human immunodeﬁciency virus (HIV) -infected in-
dividuals. Romania has a highly homogeneous cohort of HIV-
infected patients infected parenterally during their ﬁrst years
of life (1987–1990), with HIV clade F1. A substantial percentage
(78%) of this cohort has serological evidence of past or present
HBV infection [3], possibly acquired concomitantly with HIV
infection. We aimed to evaluate the presence and genotypic
characteristics of HBV DNA in the cerebrospinal ﬂuid (CSF) in
a group of patients from this cohort.Materials and methodsWe retrospectively analysed all available stored paired blood
plasma and CSF samples (between 2003 and 2009) from HIV-1-
infected children with a positive plasma hepatitis B surface an-
tigen who were undergoing a lumbar puncture for diagnosis of
CNS disorders. HBV viral loads were measured using the
Cobas Amplicor HBV Monitor Test (Roche Diagnostics, Man-
nheim, Germany), with a linear range of 60–38000 IU/mL. HIV-
1 viral loads were determined using Cobas Amplicor HIV-1
Monitor v1.5 (Roche Diagnostics), with a linear range of
50–100000 copies/mL (ultrasensitive method), and
400–750 000 copies/mL (standard method). The integrity of
the blood–brain barrier was evaluated using a CSF/serum al-
bumin index [4], with normal value <9.
In a subgroup of ﬁve patients with sufﬁcient volume of stored
paired CSF–plasma samples and an HBV viral load of >1000 IU/
mL, the presence of antiviral-resistant variants was analysed
using INNO-LiPA HBV DR v2 (Innogenetics NV, Ghent,
Belgium), a reverse hybridization line probe assay, that can
detect genetic variants and minority virus populations not evi-
denced by sequencing [5]. In one patient we performed
population-based sequencing of HBV DNA from blood and CSF
(Abbot, North Chicago, IL, USA).Clin Microbiol Infect 2015; 21: 387.e5–387.e8
al Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.11.012
TABLE 1. Demographic, clinical and laboratory characteristics of the HBsAg-positive patients with paired cerebrospinal
ﬂuid–plasma samples
No. of patients 26
Gender M/F 15/11
Age at diagnosis of HIV- infection (years) Median (limits) 10 (1–20)
Age at diagnosis of neurological complication (years) Mean ± SD 17.0 ± 2.12
HIV-1 transmission route Parenteral (non-IDU) 25
Vertical 1
CD4 count (lf/mm3) Median (range) 164 (1–738)
Mean HIV RNA ± SD (log10 copies/mL) Plasma 3.86 ± 1.40
CSF 3.07 ± 1.18
History of exposure to ART 20
History of exposure to 3TC 18
On ART containing 3TC before the neurological complication 15
HBV markers HBeAg positive 13 of 22 tested
HDV antibodies positive 4 of 20 tested
HBV DNA plasma (IU/mL) mean ± SD 4.7 ± 2.63***
HBV DNA CSF (IU/mL) mean ± SD 2.74 ± 1.33***
Positive HBV DNA (>60 IU/mL) Plasma 18 patients
CSF 11 patients
HBV DNA log10 IU/mL in patients exposed to 3TC before lumbar puncture (n = 15) Mean Plasma values
Mean CSF values
3.57 ± 2.10**
2.16 ± 0.92*
HBV DNA log10 IU/mL in patients not exposed to 3TC before lumbar puncture (n = 11) Mean Plasma values
Mean CSF values
6.26 ± 2.55**
3.54 ± 1.42*
*p < 0.01; **p 0,007; ***p 0.0001.
Abbreviations: 3TC, lamivudine; ART, antiretroviral treatment; CSF, cerebrospinal ﬂuid; HbeAg, hepatitis B e antigen; HBV, hepatitis B virus; HDV, hepatitis D virus; HIV, human
immunodeﬁciency virus; IDU, intravenous drug user.
387.e6 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIResultsThe study group consisted of 26 individuals (15 males) infected
parenterally (Table 1). All had evidence of chronic hepatitis B
without cirrhosis or hepatic insufﬁciency and alanine amino-
transferase values less than two times the upper limit of the
normal range. None of the participants had histological evalu-
ation for liver ﬁbrosis. HBV DNA was quantiﬁed in all 26
participants: 18 had detectable levels in the blood (mean
6.01 ± 2.09 log10 IU/mL) and 11 in the CSF also (mean
4.06 ± 1.06 log10 IU/mL) (Table 2). Viral loads were signiﬁcantly
different between compartments (p < 0.0001), but positively
correlated (r = 0.82, p < 0.0001, 95% CI for r = 0.64 to 0.92).
Additionally, there was a positive correlation between HBV
DNA and HIV RNA copy number in plasma and CSF (plasma
r = 0.59, p 0.001; CSF r = 0.49, p 0.01). None of the eight
patients with undetectable plasma HBV DNA had detectable
CSF HBV DNA.
Twenty participants were taking combination antiretroviral
therapy (cART) at the time of lumbar puncture and 18 had
received cART regimens containing lamivudine. None of the
participants had previous or current use of other anti-HBV
nucleotide/nucleoside analogues. Out of 15 participants
currently exposed to lamivudine, 12 patients had undetectable
CSF HBV DNA. Five of the 15 patients were failing their cART
regimen, but only two of them had detectable HBV DNA.
In ﬁve participants with detectable HBV DNA in blood and
CSF (four of them with previous exposure to lamivudine), HBV
genotypic analysis for drug resistance was performed. Two
participants demonstrated concordant proﬁles in blood andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectCSF. The other three participants demonstrated HBV genotypic
resistance and genotypic discordance between blood and CSF.
Two had the primary resistance mutation M204V and the
compensatory L180M mutation, in both the blood and CSF,
while having the V173L mutation only in plasma and rtA181T
mutation only detectable in CSF. One participant had the HBV
mutations L180M, M204V and A181T only detectable in CSF
and for the patient in whom we performed a population-based
sequencing of HBV DNA isolated from blood and CSF there
were no differences between the sequences.
DiscussionThis is the ﬁrst report to document the presence of HBV DNA
in the CSF of HIV/HBV co-infected patients and to provide
evidence of HBV compartmentalization between blood and
CSF. These ﬁndings may be important in understanding how
HBV affects the CNS, in the setting of HIV co-infection. A
strong association between HIV presence and expression of
DNA viruses, including HBV, was shown in vitro [6]. Accord-
ingly, in our study all subjects with HBV DNA in the CSF also
had detectable CSF HIV RNA.
Although not all patients with detectable plasma HBV DNA
also had detectable viral load in the CSF, in several subjects there
was evidence of CNS compartmentalization through genotypic
analysis of HBV drug resistance mutations as conﬁrmed by a
previous report [2]. This suggests that HBV can replicate inde-
pendently in the CNS. which may function as a sanctuary during
the development of HBV drug resistance similar to what has
been demonstrated for HIV [7]. Interestingly, most of theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 387.e5–387.e8
TABLE 2. Patient immunological, serological and virological proﬁles.
Patient
ID# Gender
Age
(years)
CD4
(cells/
mL)
Hbe
Ag
HDV
Ab
HBV DNA
plasma
log10 IU/mL
HBV DNA
CSF
log10 IU/mL
HIV RNA
plasma
log10 c/mL
HIV RNA
CSF
log10 c/mL
Albumin
index
(N < 9)
CSF
albumin
levels (g/L)
CSF pleocytosis
(WBC/mL of CSF)
Previous
cART
Length of current
exposure to 3TC
(months)
Neurological
diagnosis
MRI
demyelinating
lesions
1 M 21 7 N/A N/A 9.46 4.7 4.61 4.3 10.81 0.4 4 no — HIVE yes
2 F 16 125 pos N/A 8.84 3.36 6.01 2.48 N/A N/A N/A yes — stroke yes
3 M 18 37 N/A N/A 8.72 4.69 2.79 2.6 18.86 0.66 46 yes 5 stroke yes
4 M 17 490 pos N/A 8.24 5.58 5.11 5.85 27.73 0.99 5 yes — HIVE yes
5 M 17 220 N/A N/A 7.65 5.36 4.18 3.44 17.55 0.66 N/A no — viral encephalitis no
6 F 15 8 N/A N/A 7.54 3.42 4.58 2.72 2.62 0.1 3 no — viral encephalitis yes
7 F 20 59 pos neg 6.87 4.12 5.92 5.78 8.88 0.3 10 yes 2 CMV encephalitis yes
8 M 14 13 pos neg 6.34 3.3 5.34 4.36 12.35 0.4 5 No — Tx —
9 M 17 1 pos neg 5.77 4.91 5.61 2.89 73.33 1.98 20 yes — SME yes
10 M 15 182 pos neg 5.73 2.98 5.15 2.59 15.31 0.66 1 yes — facial paresis normal
11 F 20 348 pos N/A 5.73 1.78 4.11 3.32 6.01 0.2 3 no — HIVE —
12 M 16 380 pos N/A 5.07 1.78 2.25 2.25 2.06 0.1 3 yes 60 stroke —
13 M 14 19 pos neg 4.85 1.78 5.82 3.69 2.78 0.1 1 yes 49 PML yes
14 F 20 231 neg N/A 4.6 2.26 3.6 2.6 2.49 0.1 4 yes 13 SME yes
15 M 15 7 pos N/A 3.38 1.78 2.6 2.6 16.92 0.66 3 yes 1 PML yes
16 M 16 306 pos pos 3.24 1.78 2.6 2.6 2.65 0.1 2 yes 9 behaviour changes no
17 M 17 16 neg pos 3.15 1.78 4.8 2.6 2.53 0.1 1 yes 29 SME yes
18 F 18 325 neg neg 3.03 1.78 3.79 2.25 18.33 0.66 6 yes 36 epilepsy normal
19 F 16 8 pos pos 1.78 1.78 3.2 2.6 2.90 0.1 3 yes 45 evaluation Hodgkin
lymphoma
normal
20 F 16 305 neg N/A 1.78 1.78 3.62 4 33.08 1.32 22 yes viral encephalitis —
21 M 16 1 neg pos 1.78 1.78 2.25 2.43 3.65 0.1 3 yes 42 SME yes
22 F 18 220 neg neg 1.78 1.78 1.7 1.7 2.54 0.1 12 yes 22 HIVE no
23 M 18 738 N/A N/A 1.78 1.78 1.7 1.7 2.45 0.1 2 yes 69 HIVE —
24 F 20 406 neg neg 1.78 1.78 1.67 1.67 2.34 0.1 2 yes 24 HIVE —
25 F 19 255 neg neg 1.78 1.78 2.72 1.7 2.38 0.1 4 yes 9 HIVE —
26 M 21 146 neg neg 1.78 1.78 4.8 5.1 6.90 0.2 22 no — HIVE yes
Abbreviations: HBe Ag, hepatitis B e antigen; HDV Ab, hepatitis D virus antibodies; HBV, hepatitis B virus; CSF, cerebrospinal ﬂuid; WBC, white blood cells; cART, combination antiretroviral therapy; HIVE, HIV encephalopathy; SME, measles
inclusion body encephalitis or subacute myoclonic measles encephalitis; PML, progressive multifocal leucoencephalopathy; Tx, cerebral toxoplasmosis.
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387.e8 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIsubjects with current exposure to lamivudine had undetectable
HBV in the CSF, although it is known that prolonged lamivudine
therapy induces emergence of HBV-resistant variants at a higher
rate in HIV–HBV co-infected patients than in HBV mono-
infected ones [8].
Although informative, our observational study has several
limitations: the small number of subjects and absence of mono-
infected control groups limited the power to determine the
clinical signiﬁcance of the presence or level of HBV in the CSF
for neurological dysfunction, absence of longitudinal analyses,
and clonal sequence analysis of HIV or HBV on the paired
samples.
In summary, we show presence of HBV DNA in the CSF in a
number of HIV/HBV co-infected individuals, and using genotypic
analysis we demonstrate that there is compartmentalization of
HBV between the CSF and plasma. Nonetheless, it is still un-
clear if presence of HBV DNA in the CSF is associated with
neurological complications or if antiretroviral regimens con-
taining lamivudine may beneﬁt the HIV/HBV co-infected pa-
tients with neurological disease but we believe that this is a
promising lead to pursue.Transparency declarationThe authors declare that they have no conﬂicts of interest.Authorship/ContributionDD designed the study; LE collected the data and drafted the
manuscript; GT, SR and SM performed the laboratory tests; DD,
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